Science vs. Systems · №03
Some medicines are missing not because too few children need them — but because they're too hard to make.
There's a class of pediatric therapies where the demand is real and the science is sound, and they still never reach a shelf. Not for lack of a market, but because making them, handling them, or bearing the risk of them costs more than any sponsor could earn back.
We call it the Complex Compound.
The science says yes; the cost of making it says no
A complex compound can be defeated by any number of things that have nothing to do with whether it works: a manufacturing process too intricate or too low-volume to be economical, a formulation that's punishing to get right for small bodies, a cold chain, a short shelf life, a liability profile no commercial entity will shoulder. The medicine is real. The economics of producing it are not.
A different barrier — the same dead end
This is the opposite of the small-market problem, and its close cousin. An orphan asset fails on the demand side: too few patients to pay it back. A complex compound fails on the supply side: too costly or too risky to make at a profit. Different mechanisms, same result — no rational sponsor will take it on.
It can be made. It just can't be made to pay.
The answer
This is the second reason the PediaMed Institute exists. Where a medicine is genuinely needed but no one can profitably make it, philanthropy can absorb the cost and the risk the market never will. We fund the hard part — the manufacturing, the complexity, the liability — so a sound medicine that would otherwise never be produced actually gets made.
Bring us the complex compound
If there's a therapy you know is right but impossible to justify making — too complex, too costly, or too risky to ever turn a profit — that's precisely our ground. Bring us the complex compound.
The science is ready. The system isn't. That's exactly where we work.